Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 17, 2021 - Issue 1
Submit an article Journal homepage
1,046
Views
9
CrossRef citations to date
0
Altmetric
Research Paper

Vaccination pattern of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Hangzhou, China: a coverage and adverse events following immunization of different age groups

Yan Liua Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, Zhejiang, ChinaCorrespondence[email protected]
View further author information
,
Yuyang Xua Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, Zhejiang, ChinaView further author information
,
Jun Wanga Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, Zhejiang, ChinaORCID Iconhttps://orcid.org/0000-0001-6165-6220View further author information
ORCID Icon,
Xinren Chea Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, Zhejiang, ChinaView further author information
,
Wenwen Gua Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, Zhejiang, ChinaView further author information
,
Jian Dua Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, Zhejiang, ChinaView further author information
,
Xiaoping Zhanga Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, Zhejiang, ChinaView further author information
,
Xuechao Zhanga Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, Zhejiang, ChinaView further author information
,
Wei Jianga Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, Zhejiang, ChinaView further author information
,
Junfang Chena Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, Zhejiang, ChinaView further author information
&
Zhijie Anb Department of National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, ChinaORCID Iconhttps://orcid.org/0000-0002-1552-6684View further author information
ORCID Icon show all
Pages 157-161 | Received 08 Feb 2020, Accepted 30 Apr 2020, Published online: 12 Jun 2020

References

  • Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L, Reithinger R, Muenz LR, O’Brien KL. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 2010;7(10):pii: e1000348. doi:10.1371/journal.pmed.1000348.
  • WHO.23-valent pneumococcal polysaccharide vaccine: WHO position paper, October 2008, WER 2008, vol.83.p. 737–384.
  • WHO. Meeting of the immunization strategic advisory group of experts, November 2007 – conclusions and recommendations. Wkly Epidemiol Rec. 2008;83(1):1–15.
  • Wang HQ, an ZJ. Expert consensus on immunization for prevention of pneumococcal disease in China (2017) . Chin J Epidemiol. 2018;39:111–38.
  • Williams WW, Lu PJ, O’Halloran A, Kim DK, Grohskopf LA, Pilishvili T. Surveillance of vaccination coverage among adult populationsÐUnited States, 2014. MMWR Surveill Summ. 2016;65(1):1± 36. PMID:26844596. doi:10.15585/mmwr.ss6501a1.
  • Liu S, Xu E, Liu Y, Xu Y, Wang J, Du J, Zhang X, Che X, Gu W. Factors associated with pneumococcal vaccination among an urban elderly population in China. Hum Vaccin Immunother. 2014;10(10):2994–99. doi:10.4161/21645515.2014.972155.
  • Chen CH, Wu MS, Wu IC. Vaccination coverage and associated factors for receipt of the 23-valent pneumococcal polysaccharide vaccine in Taiwan. Medicine. 2018;97(5):e9773. doi:10.1097/MD.0000000000009773.
  • Wang Y, Jingxin L, Wang, Yuxiao Y, Gu W, Zhu F. Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations. Hum Vaccin Immunother. 2018;14(4):1003–12. doi:10.1080/21645515.2017.1409316.
  • United Nations Department of Economic and Social Affairs Population Division. World population prospects: the 2015 revision, key findings & advance tables. Working paper no. ESA/P/WP.241. 2015 [accessed 2016 Nov 3]. https://esa.un.org/unpd/wpp/publications/files/key_findings_wpp_2015.pdf
  • Kraicer-Melamed H, O’Donnell S, Quach C. The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: A systematic review and meta-analysis. Vaccine. 2016;34(13):1540–50. doi:10.1016/j.vaccine.2016.02.024.
  • Ogilvie I, Khoury AE, Cui Y, Dasbach E, Grabenstein JD, Goetghebeur M. Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: A systematic review of conclusions and assumptions. Vaccine. 2009;27(36):0–4904. doi:10.1016/j.vaccine.2009.05.061.
  • Zhao D, Gai Tobe R, Cui M, He J, Wu B. Cost-effectiveness of a 23-valent pneumococcal polysaccharide vaccine immunization programme for the elderly in Shanghai, China. Vaccine. 2016;34(50):6158–65. doi:10.1016/j.vaccine.2016.11.003.
  • Miller ER, Moro PL, Cano M, Lewis P, Bryant-Genevier M, Shimabukuro TT. Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990–2013. Vaccine. 2016;34(25):2841–46. doi:10.1016/j.vaccine.2016.04.021.
  • Zhang M, Zhou BL, Li W. Safety investigate of 23- valent pneumococcal poly saccharide vaccine . J Preventive Med Inf. 2013;29(9):798–800.
  • Ye JK, Li KL, Xu DS. Analysis of surveillance for adverse events following immunization in China, 2014. Chin J Vaccines Immunization. 2016;22(2):125–37.
  • Plotkin SA, Orenstein WA, Offit PA. Vaccines [M]. 7th ed. Philadelphia (PA): Elsevier; 2018. p. 835.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.